Back to top
more

Monte Rosa Therapeutics (GLUE)

(Delayed Data from NSDQ)

$4.30 USD

4.30
500,409

-0.66 (-13.23%)

Updated May 21, 2024 03:59 PM ET

After-Market: $4.29 -0.01 (-0.12%) 5:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for GLUE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Monte Rosa Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 232 264 346 42 -99,999
Receivables 1 8 0 0 NA
Notes Receivable 0 0 0 0 NA
Inventories 0 0 0 0 NA
Other Current Assets 3 4 3 2 NA
Total Current Assets 236 276 349 44 NA
Net Property & Equipment 34 27 12 5 NA
Investments & Advances 0 0 0 0 NA
Other Non-Current Assets 0 0 0 0 NA
Deferred Charges 0 0 0 0 NA
Intangibles 0 0 0 0 NA
Deposits & Other Assets 5 5 5 1 NA
Total Assets 304 342 366 49 NA
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 NA
Accounts Payable 11 8 7 7 NA
Current Portion Long-Term Debt 0 0 0 0 NA
Current Portion Capital Leases 0 0 0 0 NA
Accrued Expenses 15 15 10 3 NA
Income Taxes Payable 0 0 0 0 NA
Other Current Liabilities 18 0 0 20 NA
Total Current Liabilities 47 26 17 29 NA
Mortgages 0 0 0 0 NA
Deferred Taxes/Income 35 2 2 1 NA
Convertible Debt 0 0 0 0 NA
Long-Term Debt 0 0 0 0 NA
Non-Current Capital Leases 0 0 0 0 NA
Other Non-Current Liabilities 0 0 0 0 NA
Minority Interest (Liabilities) 0 0 0 68 NA
Total Liabilities 125 71 19 98 NA
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 NA
Common Stock (Par) 0 0 0 0 NA
Capital Surplus 548 504 472 0 NA
Retained Earnings -366 -231 -122 -48 NA
Other Equity -3 -2 -2 -1 NA
Treasury Stock 0 0 0 0 NA
Total Shareholder's Equity 179 271 348 -49 NA
Total Liabilities & Shareholder's Equity 304 342 366 49 NA
Total Common Equity 179 271 348 -49 0
Shares Outstanding 50.00 48.40 46.50 NA NA
Book Value Per Share 3.59 5.61 7.47 0.00 0.00

Fiscal Year End for Monte Rosa Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 193 232 178 203 233
Receivables 1 1 0 1 2
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 6 3 4 4 6
Total Current Assets 199 236 183 208 241
Net Property & Equipment 34 34 35 35 33
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 5 5 5 5 5
Total Assets 267 304 252 279 309
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 7 11 6 5 7
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 11 15 14 11 10
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 20 18 0 0 0
Total Current Liabilities 41 47 23 19 21
Mortgages 0 0 0 0 0
Deferred Taxes/Income 31 35 1 2 2
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 114 125 68 65 65
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 553 548 519 513 508
Retained Earnings -398 -366 -333 -298 -263
Other Equity -3 -3 -1 -2 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 153 179 185 214 244
Total Liabilities & Shareholder's Equity 267 304 252 279 309
Total Common Equity 153 179 185 214 244
Shares Outstanding 50.30 50.00 49.60 49.30 49.30
Book Value Per Share 3.03 3.59 3.72 4.33 4.94